Top Lorazepam Brands: Your Guide to Quality Choices

Lorazepam, a widely used medication for managing anxiety and certain seizure disorders, is available in various brands that promise efficacy and safety. Among the leading names, Ativan stands out as a well-regarded option, praised for its consistent performance in treating anxiety symptoms. Other notable brands include Loraz, known for its availability in different formulations to suit patients' varied needs, and Intensol, which offers a concentrated liquid form for those who may have difficulty swallowing tablets. To explore more about these brands and their specific use cases, continue reading below.

Illustration of lorazepam

Best brands of lorazepam in 2025

Ativan

Ativan, a brand name formulation of lorazepam, is a prominent player in the benzodiazepine market, known for its FDA-approved use in managing anxiety disorders and as a pre-anesthetic sedative. Lorazepam, under the Ativan brand, is also used off-label for alcohol withdrawal and panic disorders. In 2020, approximately 4.8 million individuals aged 12 and older misused lorazepam, highlighting its widespread use and potential for addiction. The global benzodiazepine drugs market, which includes Ativan, is expected to grow at a CAGR of 2.8% from 2022 to 2032, with North America holding a significant market share of around 37.2% in 2021. Ativan's efficacy and broad applications contribute to its popularity, despite the risks associated with benzodiazepine use. For more information on Ativan treatment, visit their website.

Loraz

Lorazepam, often branded as Ativan, is a highly regarded medication produced by several manufacturers, including Hikma and Pfizer. Hikma's Ativan injection is widely used for the treatment of status epilepticus and as a premedication for surgical procedures, despite current shortages due to increased demand. Pfizer also offers lorazepam injection, ensuring availability amidst the shortage. The global benzodiazepine market, which includes lorazepam, is forecasted to grow at a CAGR of 2.8% from 2022 to 2032, with lorazepam being a significant component. Hikma's products are particularly notable for their widespread use in hospitals and clinics. For more information on the current shortages, visit the ASHP drug shortage details.

Intensol

Lorazepam Intensol, produced by reputable manufacturers, is a highly effective benzodiazepine solution, particularly noted for its use in treating anxiety and insomnia. It is available as a concentrated solution of 2 mg per mL, making it a versatile option for various dosing needs. The global benzodiazepine market, which includes lorazepam, is projected to grow at a CAGR of 2.8% from 2022 to 2032, reaching a market size of US$ 3.1 billion by 2032. Lorazepam Intensol is administered orally, mixed with liquid or semi-solid food, and the dosage can range from 1 mg to 10 mg daily, depending on the patient's response. This formulation is not recommended for children and should be used cautiously in elderly or debilitated patients.

Lorazepam by Actavis

Lorazepam, marketed under the Actavis brand, is a highly effective short-acting benzodiazepine used for the short-term relief of anxiety symptoms, panic disorders, and seizures. It was first approved by the FDA in 1985 and is known for its rapid absorption, with an absolute bioavailability of 90% and peak plasma levels reached approximately 2 hours after administration. The drug has a mean half-life of about 12 hours and is approximately 85% bound to plasma proteins. Actavis, as one of the prominent manufacturers, ensures high-quality production, contributing to the drug's widespread use, with over 18 million prescriptions issued annually. Lorazepam is available in various forms, including oral tablets and sublingual tablets, making it a versatile option for different patient needs. For more detailed information, visit the Lorazepam product page.

Lorazepam by Teva

Lorazepam by Teva is a highly regarded anxiolytic-sedative medication, indicated for the short-term relief of excessive anxiety symptoms, particularly in patients with anxiety neurosis. It is available in 0.5 mg, 1 mg, and 2 mg tablets, each formulation carefully designed to ensure efficacy and safety. Teva's lorazepam has been authorized since March 5, 1985, and recent label changes in December 2021 highlight enhanced monitoring recommendations for geriatric patients. The medication is contraindicated in patients with myasthenia gravis, acute narrow angle glaucoma, and known hypersensitivity to benzodiazepines. Teva's commitment to quality and safety makes it one of the best producers of lorazepam. For more detailed information, please refer to the Product Monograph.

Lorazepam by Sandoz

Lorazepam by Sandoz, a well-established pharmaceutical company, is a highly effective medication for treating anxiety disorders, severe anxiety, and seizures. It is available in various formulations, including injections and tablets, with a marketed status since 2005 in Canada. The lorazepam injection by Sandoz has a strength of 4 mg/ml, ensuring rapid and effective treatment. Studies have shown that lorazepam is superior in terminating status epilepticus, with a success rate of 59.1% compared to other treatments. Its high bioavailability and rapid absorption make it a preferred choice in clinical settings. For more details about Lorazepam by Sandoz, visit their official resource page.

Lorazepam by Mylan

Lorazepam by Mylan is a significant player in the generic drug market, particularly notable for its involvement in a major price-fixing scandal in the late 1990s. In 1998, Mylan raised the wholesale price of lorazepam tablets by 1,940 percent to 2,682 percent, and the price of clorazepate tablets by 1,935 percent to 3,219 percent, following exclusive licensing agreements that deprived competitors of the necessary active pharmaceutical ingredients (APIs). This action led to a record $100 million settlement with the Federal Trade Commission (FTC) in 2000. Despite this controversy, lorazepam remains a widely prescribed medication for anxiety, tension, agitation, and insomnia, with over 18 million prescriptions issued annually. Mylan's actions highlighted the critical impact of market manipulation on drug prices and consumer access. For more detail, view the FTC press release on the Mylan case.

Lorazepam by Apotex

Lorazepam by Apotex is a highly effective and therapeutically equivalent alternative to brand-name lorazepam, such as Ativan. It is rapidly absorbed after oral administration, with mean peak plasma concentrations achieved within 2 hours, and it has a serum half-life ranging between 12 to 15 hours. The bioavailability of Apotex's lorazepam is identical across all routes of administration, with approximately 85% of the drug bound to plasma proteins. In a comparative bioavailability study, Apotex's lorazepam showed a geometric mean AUC of 747.5 ng*h/mL, closely matching the reference brand Ativan. This generic version offers significant cost savings without compromising on efficacy. For more detailed information, you can view the product monograph.

Lorazepam by Aurobindo

Lorazepam by Aurobindo Pharma is highly regarded for its efficacy and patient satisfaction, boasting an impressive rating of 8.7 out of 10 based on 1388 reviews, which highlights its reliability and effectiveness in managing anxiety and insomnia. Aurobindo Pharma, a major player in the benzodiazepine market, ensures high-quality production, contributing to the market's projected growth with a CAGR of 2.4% by 2027. With a strong presence in the global pharmaceutical industry and an extensive product portfolio, Aurobindo Pharma is a significant contributor to the benzodiazepine drugs market. Lorazepam, as a key product, is widely prescribed and consistently performs well in treating various conditions. The approval of generic versions by regulatory authorities further enhances the drug's accessibility and affordability. For more information about Aurobindo Pharma, visit their official page.

Lorazepam by Sun Pharma

Lorazepam, marketed by Sun Pharmaceutical Industries Ltd., is a highly effective short-acting benzodiazepine used for the short-term relief of anxiety symptoms and panic disorders. With a high bioavailability of 90% when administered orally, lorazepam is rapidly absorbed and achieves maximum serum concentration in 2 hours. Sun Pharma, one of the leading players in the benzodiazepine APIs market, has been consistently producing high-quality lorazepam formulations since its approval in various strengths such as 0.5mg, 1mg, and 2mg tablets. The company's focus on strategic acquisitions and partnerships has enhanced its product portfolio, contributing to the market's expected growth at a CAGR of 3.6% from 2023 to 2031. Sun Pharma's lorazepam is available in multiple formulations, including oral and injectable forms, ensuring comprehensive treatment options. For more in-depth insights into the benzodiazepine APIs market, visit the Transparency Market Research report.